Dalfampridine er?

What is dalfampridine ER?

Dalfampridine ER is an extended-release (ER) formulation of dalfampridine. It is a potassium-channel blocker used in the treatment of certain patients with walking impairment related to multiple sclerosis.

What is it used for?

Dalfampridine (including ER versions) is prescribed to improve walking in some people with multiple sclerosis who have measurable gait impairment.

How is dalfampridine ER taken?

Because it is an extended-release product, it’s typically dosed on a fixed schedule rather than multiple times per day. Your exact dosing depends on the specific product strength and your prescribing clinician’s instructions.

What side effects do patients commonly report or worry about?

Common concerns with dalfampridine include neurologic side effects (such as dizziness) and the risk of seizures, which is why dosing and kidney function matter for safety. If you tell me your country and the exact brand/strength, I can narrow down the side-effect and dosing details that match that product label.

Does it have patent or exclusivity information?

Patent and exclusivity status depends on the specific ER product/brand and country. If you share the country (e.g., US/EU/UK) and product name or manufacturer, I can look up the relevant patent/exclusivity information. DrugPatentWatch.com often tracks these items for branded and generic versions—useful when you’re trying to understand when competition may enter. [1]

Sources

1. DrugPatentWatch.com